MODERNA INC CEDEAR EACH 19 REP 1 ORD (USD)MODERNA INC CEDEAR EACH 19 REP 1 ORD (USD)MODERNA INC CEDEAR EACH 19 REP 1 ORD (USD)

MODERNA INC CEDEAR EACH 19 REP 1 ORD (USD)

No trades
See on Supercharts

Key facts today

Moderna and Pfizer reported over $3 billion in combined sales for their mRNA COVID-19 vaccines during the third quarter.
Moderna, Inc. ranked as the top large employer in BioSpace's 2025 Best Places to Work report for the fourth year in a row, highlighting its strong reputation and focus on innovation.
Analyze the impactAnalyze the impact
Market capitalization
‪16.45 B‬USD
−5.803USD
‪−4.71 B‬USD
‪6.84 B‬USD
‪343.15 M‬
Beta (1Y)
−0.39

About Moderna, Inc.


CEO
Stéphane Bancel
Headquarters
Cambridge
Founded
2010
ISIN
AR0666228538
FIGI
BBG01MDJMG13
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.